See you there! hVIVO’s Dr Rob Lambkin-Williams speaking at the International Conference on Flu

May 18, 2015 10:43 am

Dr Rob Lambkin-Williams, hVIVO (formerly Retroscreen Virology) Executive Scientific Advisor, will be speaking at the International Conference on Flu, at the North Shore Conference Centre, Skokie, Chicago USA, held from the 8 – 10 June 2015.

The three day conference, the theme of which is “Advanced Research in Flu”, anticipates the participation of experts from various cross disciplines including virologists, immunologists, microbiologists, epidemiologists, doctors, public health planners, pharmacologists, computational biologists, and those in applied fields conducting influenza related research.

Dr Lambkin-Williams will be making an oral presentation on Day two (9th June) entitled “Accelerating Influenza Research; Vaccines, Antivirals, Immunodulators and Monoclonal Antibodies. The Manufacture of a New H3N2 Virus for the Human Viral Challenge Model.”

Dr Lambkin-Williams commented: “By working together to make sure any new influenza strain is constantly monitored, the scientific community can help prevent a lethal influenza pandemic and also help reduce the yearly death toll of seasonal flu. Our own pioneering hVIVO human challenge model enables scientists to understand the behaviour of influenza in real time. From healthy volunteers experiencing a pre-determined sickness episode (often including investigational therapeutic treatment) to the recovery back to healthy state again, our insight and data is invaluable. I am looking forward to a lively three days helping to advance our knowledge in flu research.”

Find out more about the “Flu 2015” conference here.

If you would like to connect with Dr. Rob Lambkin-Williams or one of our Business Development representatives during or after the International Conference on Flu, please contact us using the below form.

Leave a Reply

Your email address will not be published. Required fields are marked *


*

Get in touch

Give us a call, or drop us an email. We'd love to hear from you!

Get in touch now